🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced today

Find Clinical Trials for Your Rare Disease

168+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 168 recruiting trials for “Systemic lupus erythematosus

Phase 1, PHASE2RecruitingNCT06121297

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

👨‍⚕️ Medical Director, Cabaletta Bio📍 23 sites📅 Started Feb 2024View details ↗
Phase 1, PHASE2RecruitingNCT06106893

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

👨‍⚕️ Qiubai Li, Professor, Department of Rheumatology and Immunology, Wuhan Union Hospital📍 1 site📅 Started Jan 2024View details ↗
RecruitingNCT06458972

Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)

👨‍⚕️ Dong Lingli, MD, Tongji Hospital📍 1 site📅 Started Jan 2024View details ↗
Phase 4RecruitingNCT05559671

Safety of the Herpes Zoster Subunit Vaccine in Lupus

👨‍⚕️ Amit Saxena, MD, NYU Langone Health📍 2 sites📅 Started Dec 2023View details ↗
RecruitingNCT05845593

Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)

🏥 Ampel BioSolutions, LLC📍 11 sites📅 Started Dec 2023View details ↗
Phase 1RecruitingNCT05835986

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus

👨‍⚕️ Clinical Trials, Hoffmann-La Roche📍 24 sites📅 Started Dec 2023View details ↗
NARecruitingNCT05714930

LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus

👨‍⚕️ Matthias Schneider, MD, Heinrich-Heine University, Duesseldorf📍 14 sites📅 Started Dec 2023View details ↗
Phase 2RecruitingNCT05440422

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

👨‍⚕️ Mariana J Kaplan, M.D., National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)📍 1 site📅 Started Dec 2023View details ↗
RecruitingNCT06462768

Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis

🏥 CHU de Reims📍 1 site📅 Started Nov 2023View details ↗
EARLY_Phase 1RecruitingNCT06010472

An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus

👨‍⚕️ Dongbao Zhao, Doctor, ChanghaiHospital📍 1 site📅 Started Aug 2023View details ↗
NARecruitingNCT05988216

Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus

🏥 Bioray Laboratories📍 1 site📅 Started Aug 2023View details ↗
RecruitingNCT05859191

Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus

👨‍⚕️ Yanis RAMDANI, CHRU de Tours📍 1 site📅 Started Jul 2023View details ↗
Phase 1, PHASE2RecruitingNCT06347718

CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease

👨‍⚕️ Georg Schett, Prof. Dr. med. univ., Universitätsklinikum Erlangen📍 1 site📅 Started Jul 2023View details ↗
Phase 4RecruitingNCT05916781

Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus

👨‍⚕️ Mengtao Li, MD, Peking Union Medical College Hospital📍 1 site📅 Started Jul 2023View details ↗
RecruitingNCT05934149

Lupus Landmark Study: A Prospective Registry and Biorepository

👨‍⚕️ Sam Lim, MD, MPH, Emory University📍 21 sites📅 Started Jun 2023View details ↗
Phase 4RecruitingNCT05828147

Anti-CD20 Antibodies for Treatment of SLE-PAH

👨‍⚕️ Mengtao Li, Prof, Peking Union Medical College Hospital📍 1 site📅 Started May 2023View details ↗
NAEnrolling by InvitationNCT05859997

Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases

🏥 Bioray Laboratories📍 1 site📅 Started May 2023View details ↗
Phase 2RecruitingNCT05688696

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

🏥 Beijing InnoCare Pharma Tech Co., Ltd.📍 41 sites📅 Started Apr 2023View details ↗
Phase 2RecruitingNCT05680480

A Study of Telitacicept in Lupus Nephritis

🏥 RemeGen Co., Ltd.📍 45 sites📅 Started Apr 2023View details ↗
Phase 3RecruitingNCT05339217

Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus

👨‍⚕️ Zhanguo Li, Peking University Institute of Rheuamotology and Immunology📍 1 site📅 Started Feb 2023View details ↗
← PreviousPage 7 of 9Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →